Protocol Ledger

NCT05090891 · Phase II · RECRUITING

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Interventional Phase II clinical trial protocol NCT05090891 sponsored by Incyte in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-05 Enrollment: 98 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05090891
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05090891
Protocol FieldVerified Registry Value
NCT IdentifierNCT05090891
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment98 participants (ESTIMATED)
Registered Start Date2022-05-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05090891
Hospital Research SiteLocationSite Profile
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Children's Hospital of PhiladelphiaPhiladelphia, PAOpen Hospital Dossier ->
Hospital Italiano de Buenos AiresBuenos Aires, ArgentinaOpen Hospital Dossier ->
Royal North Shore HospitalSt Leonards, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI